Highbridge Multi Strategy edges ahead in 2017 – Highbridge Multi Strategy Fund generated a return of 3.7% on its NAV over the course of 2017. The total return of the S&P 500 in 2017 was +21.8%. This might look like an unexciting return but it is consistent with returns earned by most other absolute return […]
NB Private Equity Partners dollar gains wiped out by sterling strength – The highlights from NB Private Equity’s results for 2017 are: 31 December 2017 Net Asset Value per share of $17.45 increased $1.54 from $15.91 at 31 December 2016. However, in sterling term the move translated to a 2p rise from GBP12.89 to GBP12.91 NAV total return of 13.2% NAV increase […]
Investment Trust Insider on Supermarket Income REIT James Carthew: Supermarket Inc should go down main aisle Last summer Supermarket Income (SUPR) presented investors with a new alternative in their search for predictable, inflation-linked yields. Since then the real estate investment trust (Reit) has announced quarterly dividends of 1.375p, equating to a 5.5% yield on its […]
Juridica left with seven cases – During 2017, Juridica’s NAV per share dropped by US$0.0977 per share from US$0.2541 per share at 31 December 2016 to US$0.1563 per share at 31 December 2017. mostly this relates to the payment of dividends amounting to US$11.9 million (US$0.1074 per share) but it also made a profit during 2017 of US$1.1 million (US$0.0097 per […]
Trust favourite Alnylam sees shares tank on competitor success US RNAi therapeutic specialist Alnylam Pharmaceuticals (Nasdaq:ALNY) has seen its shares fall by 22% over the long Easter weekend, principally on news of a surprise positive clinical trial result for a potential competitor to its lead product patisiran, which has been developed initially for hereditary transthyretin-mediated amyloidosis […]
HBM Healthcare to benefit from Homology Medicines IPO Swiss-listed HBM Healthcare (HBMN) is set to receive a modest boost to its NAV following the US initial public offering last week of Homology Medicines (Nasdaq: FIXX), a US gene editing/gene therapy company developing treatments for rare disease. Homology raised a total of $165.6m from an offering of 10.35m shares at $16.00 […]
WPCT gets surprise boost up trust leaguetable from Prothena deal An unexpected recovery in Woodford Patient Capital Trust (WPCT)’s share price last month on the back of the collaboration signed between investee Prothena (NASDAQ:PRTA) and Celgene (NASDAQ:CELG), has made the struggling investment trust the surprise top performer among the sector specialist funds in March, albeit amid […]
3i Infrastructure makes investment in Attero – 3i Infrastructure will invest €201m to acquire a 50% stake in Attero, one of the largest waste treatment and disposal companies in the Netherlands. 3i Infrastructure will invest alongside DWS’s infrastructure investment business (formerly Deutsche Asset Management) to acquire Attero from Waterland, a Dutch private equity fund. 3i […]
‘Experienced. Disciplined. Determined. All you want from a hero.’ – Merchants Trust outperformed the All-Share, its benchmark index over the year to the end of January 2018. Its NAV total return was +14.5% with debt at market value, outperforming the benchmark total return of +11.3%. This investment return placed the company 6 out of 25 funds in […]
BBGI plans small fund raise – BBGI SICAV results for 2017 have been published. Highlights are: NAV up 14.2% to GBP622.5 million as at 31 December 2017 (GBP545.0 million – 31 December 2016). NAV per share up 3.0% to 129.9 pence as at 31 December 2017 (126.1 pence – 31 December 2016). During the year, the Board […]
